# **Investor presentation**

#### Raymond James Investor Conference March 2018





Copyright © 2017 HealthEquity, Inc. All rights reserved.

### **Safe Harbor**

This presentation does not constitute an offer or invitation for the sale or purchase of securities and has been prepared solely for informational purposes. This presentation is a summary of information contained in our public filings filed with the Securities and Exchange Commission (SEC), which public filings are expressly incorporated herein by reference (see <u>http://ir.healthequity.com/</u>), and other publicly available information. Readers are encouraged to review our public filings for further information.

This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, statements regarding our industry, business strategy, plans, goals and expectations concerning our market position, product expansion, future operations, margins, profitability, future efficiencies, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words "may," "believes," "intends," "seeks," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "will," "future" and the negative of these or similar terms and phrases are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our management's beliefs and assumptions only as of the date of this presentation. Our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Readers are encouraged to review our public filings with the SEC for further disclosure of other factors that could cause actual results to differ materially from those indicated in any forward-looking statements included herein.


This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

This presentation includes certain non-GAAP financial measures as defined by SEC rules. As required by Regulation G, we have provided a reconciliation of those measures to the most directly comparable GAAP measures, which is available in our public filings.

No part of this presentation may be copied, recorded, or rebroadcast in any form.




#### **Investment highlights**




HealthEquity data measured for fiscal years 2014 to 2017
Based on Devenir Research HSA reports December 31, 2010-2017



### **Key metrics**




## **Rising first dollar responsibility**



Deductible for Family Plan



#### **Our core – health savings accounts**




**\$1,900** Average premium savings<sup>1</sup>

\$1,417 Average employer contribution<sup>1</sup> **\$6,900** Maximum family HSA contribution



#### **Expanding market**




MARKET WIDE REVENUE



### **Growing market share**




#### HealthEquity HSAs market share





### **Proprietary end-to-end platform**





#### **FY 18 sales results**




- Largest HSA take away
- Preferred relationship agreements with Blue Cross Blue Shield Association and Health Plan Alliance

Renewal of
Anthem partnership




#### **Powerful monetization**





### **Growing forward**





### Account balance growth by age









Devenir Research HSA report December 31, 2017
HealthEquity data as of January 31, 2018

#### **Value of mature accounts**






### **Rising above**






### **Fiscal year 2018 operating results**




- New organic HSAs of 669K vs 668K YoY
- An additional 54K FIBK and Alliant CU HSAs
- 24% growth in ending HSAs YoY




- Net increase of \$1.7B YoY
- 35% growth YoY

#### Health Equity<sup>®</sup>



- 31% Q3 revenue growth YoY
  - 22% Q3 growth in Service Revenue
  - 48% Q3 growth in Custodial Revenue
  - 22% Q3 growth in Interchange Revenue



- 46% Adjusted EBITDA growth Q3 YoY
- Q3 Gross margins 59%
- Q3 Operating margins 24%

#### Health Equity®

(\$ in millions)	January 31, 2017	October 31, 2017	
Cash, cash equivalents & marketable securities	\$180.4	\$225.1	
Long-term debt (\$100M available LOC)	\$0.0	\$0.0	
Total equity	\$261.9	\$334.4	





	Business	Outlook
--	----------	---------

#### For the Fiscal Year Ending January 31, 2018

Guidance as of: (\$ in millions, except per share)	December 5, 2017*	September 5, 2017	June 6, 2017	March 21, 2017
Revenue	\$225 - \$228	\$223 – \$228	\$222 - \$227	\$220 - \$225
Non-GAAP Net Income**	\$39 - \$41	\$39 - \$43	\$38 - \$42	
Non-GAAP EPS diluted**	\$0.64 - \$0.66	\$0.64 - \$0.68	\$0.62 - \$0.67	
Adjusted EBITDA**	\$80 - \$83	\$79 – \$84	\$78 - \$83	\$77 - \$82

\*Guidance issued in press release dated December 5, 2017. We do not undertake to update this guidance, which speaks only as of the date given. \*\* See press release on December 5, 2017, for a reconciliation of net income, the most comparable GAAP measure, to Non-GAAP Net Income, Non-GAAP EPS and Adjusted EBITDA. HealthEquity®